Company Overview and News

 
Nikkei, Topix hit multi-month peaks on receding trade fears

2018-09-21 reuters
TOKYO, Sept 21 (Reuters) - Japanese stock indexes hit multi-month highs on Friday as ebbing concerns about global trade tensions and bullish views on the U.S. economy supported commodities and manufacturing firms.
5411 8750 JFEEF

2
Nikkei jumps to 8-month high

2018-09-21 thehindubusinessline
The Nikkei share average gained 0.8 per cent to 23,864.04 in midmorning trade, the highest level since January 24. - Reuters
8316 8306 MUFG SMFG 5411 8750 JFEEF SMFNF MBFJF MTU

 
Nikkei at 8-mth highs, Wall St rally makes markets less edgy over trade

2018-09-21 theedgemarkets
TOKYO (Sept 21): Japan's Nikkei advanced to fresh eight-month highs led by an upbeat Wall Street performance, with commodity stocks rising as investors appeared to gravitate to the view that the U.S.-China trade row would be less damaging to growth than first feared.
5411 8750 JFEEF

 
REFILE-Nikkei at 8-mth highs, Wall St rally makes markets less edgy over trade

2018-09-21 reuters
TOKYO, Sept 21 (Reuters) - Japan’s Nikkei advanced to fresh eight-month highs led by an upbeat Wall Street performance, with commodity stocks rising as investors appeared to gravitate to the view that the U.S.-China trade row would be less damaging to growth than first feared.
5411 8750 JFEEF

 
Nikkei at 8-mth highs, Wall St rally makes markets less edgy over trade

2018-09-21 reuters
TOKYO, Sept 21 (Reuters) - Japan’s Nikkei advanced to fresh eight-month highs led by an upbeat Wall Street performance, with commodity stocks rising as investors appeared to gravitate to the view that the U.S.-China trade row would be less damaging to growth than first feared.
5411 8750 JFEEF

2
Nikkei steady as financials rise, profit taking limits gains

2018-09-20 reuters
TOKYO, Sept 20 (Reuters) - Japan’s Nikkei ended little changed on Thursday as an extended rally in financial shares were largely offset by profit taking after several days of big gains for the broader market.
MZHOF TKOMF SMFG SMFNF 8316 8306 MUFG 8766 8411 TKOMY 8750 MBFJF 8630 MTU MFG

2
Nikkei edges up as financials rise, momentum slows after extended surge

2018-09-20 theedgemarkets
TOKYO (Sept 20): Japan's Nikkei share average inched up on Thursday as financial shares extended their rise, although advances were limited as market momentum slowed after several days of big gains.
MZHOF TKOMF SMFG SMFNF 8316 8306 MUFG 8766 8411 TKOMY 8750 MBFJF 8630 MTU MFG

2
Nikkei edges up as financials rise, momentum slows after extended surge

2018-09-20 reuters
TOKYO, Sept 20 (Reuters) - Japan’s Nikkei share average inched up on Thursday as financial shares extended their rise, although advances were limited as market momentum slowed after several days of big gains.
MZHOF TKOMF SMFG SMFNF 8316 8306 MUFG 8766 8411 TKOMY 8750 MBFJF 8630 MTU MFG

2
Tokyo stocks rise further on easing U.S.-China trade concerns

2018-09-19 japantimes.co.jp
Stocks continued to rise on the Tokyo Stock Exchange on Wednesday as investors were relieved that the economic impact of the latest development of U.S.-China trade friction is likely to be limited.
ADTTF TM SMFG TYT SFTBF TOYOF SMFNF TOELY SUOPY 8316 8306 7203 MUFG 9984 SUMCF 8750 TOELF 8035 MBFJF ATEYY MTU SFTBY

 
Nikkei hits near 8-mth high, Topix also jumps; insurers rally after US yields rise

2018-09-19 reuters
TOKYO, Sept 19 (Reuters) - Japan’s Nikkei extended its gains to near eight-month highs on Wednesday as investors took heart from a strong performance in Wall Street despite lingering trade war concerns, with financial stocks rallying after U.S. yields jumped.
KYO TTDKF 8750 8630

2
Nikkei extends gains to near 8-month high

2018-09-19 thehindubusinessline
Exporters also rose, with Kyocera Corp adding 3.1 per cent, TDK Corp rising 3 per cent and Honda Motor Co advancing 2.4 per cent.
KYO TTDKF 8316 8306 MUFG SMFG 8750 SMFNF MBFJF 8630 MTU

 
Nikkei nears 8-month highs; insurers rally after U.S. yields rise

2018-09-19 theedgemarkets
TOKYO (Sept 19): Japan's Nikkei extended its gains to near eight-month highs on Wednesday as investors took heart from a strong performance in Wall Street despite lingering trade war concerns, with financial stocks rallying after U.S. yields jumped.
KYO TTDKF 8750 8630

 
Nikkei nears 8-month highs; insurers rally after U.S. yields rise

2018-09-19 reuters
TOKYO, Sept 19 (Reuters) - Japan’s Nikkei extended its gains to near eight-month highs on Wednesday as investors took heart from a strong performance in Wall Street despite lingering trade war concerns, with financial stocks rallying after U.S. yields jumped.
KYO TTDKF 8750 8630

1
Nikkei has best gain in 5 weeks, insurers rise and US tariffs shrugged off

2018-09-18 reuters
TOKYO, Sept 18 (Reuters) - Japan’s Nikkei rallied on Tuesday to its highest close since Feb. 1, led by insurers thanks to rising U.S. Treasury yields, though electronic suppliers underperformed as traders weighted the impact of new U.S. tariffs on Chinese goods.
KYO MRAAF AAPL MRAAY 8750

1
Nikkei rallies as insurers gain on rising US Treasury yields

2018-09-18 thehindubusinessline
Japan's Nikkei rallied on Tuesday led by gains for insurers thanks to rising US Treasury yields, though electronic suppliers underperformed as traders considered the implications of fresh US tariffs on Chinese goods.
KYO MRAAF AAPL MRAAY 8750

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...